Common use of Studies Clause in Contracts

Studies. The preclinical studies and clinical trials conducted by, on behalf of or sponsored by the Company or its subsidiaries, or in which the Company or its subsidiaries participated, were and, if still pending are being, conducted in all material respects in accordance with the experimental protocols established for each study and trial and with all applicable local, state and federal laws, rules and regulations, including, without limitation, the Federal Food, Drug, and Cosmetic Act and its applicable implementing regulations; the descriptions of the results of such studies and trials contained in the General Disclosure Package or the Final Prospectus are accurate and complete in all material respects and fairly present the data derived from such studies and trials; except to the extent disclosed in the General Disclosure Package and the Final Prospectus, the Company is not aware of any studies or trials, the results of which are inconsistent with or otherwise call into question the study and trial results described or referred to in the General Disclosure Package or the Final Prospectus; and neither the FDA nor any applicable foreign regulatory agency has commenced, or, to the knowledge of the Company, threatened to initiate, any action to place a hold order on, or otherwise terminate, delay or suspend, any proposed or ongoing preclinical studies or clinical trials conducted or proposed to be conducted by or on behalf of the Company.

Studies. The preclinical pre-clinical studies and clinical trials (as applicable) conducted by, on behalf of or sponsored by the Company or its subsidiaries, or in which the Company or its subsidiaries or their product candidates participated, were and, if still pending are being, conducted in all material respects in accordance with the experimental protocols established for each study and trial and with all applicable local, state Licenses and federal laws, rules and regulationsHealth Care Laws, including, without limitation, the Federal Food, DrugDrug and Cosmetic Act, the Public Health Service Act, and Cosmetic Act and its their applicable implementing regulations; the descriptions of the results of such studies and trials contained in the General Disclosure Package or the Final Prospectus are accurate and complete in all material respects and fairly present the data derived from such studies and trialsmaterial studies; except to the extent disclosed in the General Disclosure Package and the Final Prospectus, the Company is not aware of any studies or trialsstudies, the results of which are inconsistent with or otherwise call into question the study and trial results described or referred to in the General Disclosure Package or the Final Prospectus; and neither the FDA nor any applicable foreign regulatory agency has commenced, or, to the knowledge of the Company, threatened to initiate, any action to place a hold order on, or otherwise terminate, delay or suspend, any proposed or ongoing preclinical studies or clinical trials conducted or proposed to be conducted by or on behalf of the Company.

Studies. The preclinical pre-clinical studies and clinical trials (as applicable) conducted by, on behalf of or sponsored by the Company or its subsidiaries, or in which the Company or its subsidiaries or their product candidates participated, were and, if still pending are being, conducted in all material respects in accordance with the experimental protocols established for each study and trial and with all applicable local, state Licenses and federal laws, rules and regulationsHealth Care Laws (as defined below), including, without limitation, the Federal Food, DrugDrug and Cosmetic Act, the Public Health Service Act, and Cosmetic Act and its their applicable implementing regulations; the descriptions of the results of such studies and trials contained in the General Disclosure Package or the Final Prospectus are accurate and complete in all material respects and fairly present the data derived from such studies and trialsstudies; except to the extent disclosed in the General Disclosure Package and the Final Prospectus, the Company is not aware of any studies or trialsstudies, the results of which are inconsistent with or otherwise call into question the study and trial results described or referred to in the General Disclosure Package or the Final Prospectus; and neither the FDA nor any applicable foreign regulatory agency has commenced, or, to the knowledge of the Company, threatened to initiate, any action to place a hold order on, or otherwise terminate, delay or suspend, any proposed or ongoing preclinical studies or clinical trials conducted or proposed to be conducted by or on behalf of the Company.

Studies. The preclinical studies and clinical trials conducted by, on behalf of or sponsored by the Company or its subsidiaries, or in which the Company or its subsidiaries participated, were and, if still pending are being, conducted in all material respects in accordance with the experimental protocols established for each study and trial and with all applicable local, state and federal laws, rules and regulations, including, without limitation, the Federal Food, Drug, and Cosmetic Act and its applicable implementing regulations; the descriptions of the results of such studies and trials contained in the General Disclosure Package or Registration Statement and the Final Prospectus are accurate and complete in all material respects and fairly present the data derived from such studies and trials; except to the extent disclosed in the General Disclosure Package Registration Statement and the Final Prospectus, the Company is not aware of any studies or trials, the results of which are inconsistent with or otherwise call into question the study and trial results described or referred to in the General Disclosure Package or Registration Statement and the Final Prospectus; and neither the FDA nor any applicable foreign regulatory agency has commenced, or, to the knowledge of the Company, threatened to initiate, any action to place a hold order on, or otherwise terminate, delay or suspend, any proposed or ongoing preclinical studies or clinical trials conducted or proposed to be conducted by or on behalf of the Company.